^
    10d
    IRST185.04: Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) (2024-511660-89-00)
    P1/2, N=70, Active, not recruiting, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • prednisone • Xofigo (radium Ra-223 dichloride)
    16d
    COMRADE: Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis (clinicaltrials.gov)
    P1/2, N=145, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Feb 2027 | Trial primary completion date: Apr 2026 --> Mar 2025
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    CD4 (CD4 Molecule)
    |
    Lynparza (olaparib) • Xofigo (radium Ra-223 dichloride)
    29d
    BAT-RAD: Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=47, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Feb 2027 --> Feb 2029 | Trial primary completion date: Feb 2026 --> Feb 2028
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Xofigo (radium Ra-223 dichloride)
    1m
    Remarkable Response to Etoposide and Cisplatin in Aggressive-Variant Prostate Cancer With Low Prostate-Specific Antigen Levels: A Case Report. (PubMed, Cureus)
    Subsequent radium-223 therapy further reduced bone metastases and normalized ALP levels, leading to substantial functional recovery. Furthermore, the favorable response to EP highlights the potential role of platinum-based chemotherapy in managing low-PSA, high-grade PC. Additional cases are needed to refine the clinical characterization of AVPC and establish evidence-based treatment guidelines.
    Journal
    |
    AR (Androgen receptor) • SYP (Synaptophysin) • NKX3-1 (NK3 homeobox 1)
    |
    cisplatin • etoposide IV • Xofigo (radium Ra-223 dichloride)
    1m
    Low-Count Quantitative SPECT for Men Treated With Radium-223 (clinicaltrials.gov)
    P=N/A, N=38, Not yet recruiting, Washington University School of Medicine | Trial completion date: Nov 2027 --> Mar 2028 | Initiation date: Nov 2025 --> Mar 2026 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Radium-223 in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | N=54 --> 2 | Trial completion date: May 2028 --> Mar 2027 | Trial primary completion date: May 2026 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    DORA: A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=732, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • Xofigo (radium Ra-223 dichloride)
    2ms
    In-situ ²²³Ra-doped calcium-alginate composite microspheres: a high-LET and immunoactivating platform for α-particle radioembolization in hepatocellular carcinoma. (PubMed, J Nanobiotechnology)
    Transcriptomics reveals activation of DNA-damage response, immunogenic cell death, and antigen-presentation pathways, flow cytometry and immunohistochemistry show increased dendritic-cell maturation and CD8⁺ T-cell infiltration. Collectively, 223Ra/Ca-ALG MS demonstrates hypoxia-tolerant cytotoxicity, immune-activating potential, offering new insights for the development of immune-based TARE strategies in HCC and showing promising prospects for clinical translation.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    An Integrated Analysis of Four Targeted Thorium Conjugates to Assess the 227Th and 223Ra Distribution and Tissue-Related Radiation. (PubMed, Cancer Biother Radiopharm)
    In this study, the authors evaluated the distribution of thorium-227 (227Th) and its first daughter nuclide, radium-223 (223Ra), by analyzing tissue activity data from monkey studies from different antibody-based targeted thorium conjugates (hereafter called "conjugates")...The observation in monkeys that physical decay is the main elimination path for 227Th and that 223Ra undergoes a fast additional elimination in a typical tissue was consistent with clinical whole-body radioactivity data. The overarching consistency of the findings regarding tissue redistribution of 227Th and 223Ra across different conjugates and the consistency with clinical observations of whole body radioactivity in patients emphasize the importance of considering the potential redistribution of long-lived daughter nuclides of radionuclides used in therapeutic applications in humans.
    Journal
    |
    CD22 (CD22 Molecule)
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. (PubMed, Prostate Cancer Prostatic Dis)
    The changes in tumor cell numbers after Ra223 treatment seemed to be inversely correlated with changes in CD3+/CD8+ and CD4+/FoxP3+ cells, but not with other immune cells, in these 3 patients. Further characterization of immune cells in the bone-TME will be required before developing strategies to enhance immunotherapy efficacy in bmCRPC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • MRC1 (Mannose Receptor C-Type 1)
    |
    Xofigo (radium Ra-223 dichloride)
    2ms
    Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study (clinicaltrials.gov)
    P2, N=134, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Xofigo (radium Ra-223 dichloride)